Federal probe finds that just two drugs account for 90% of Medicaid rebate losses

calculator
A report from the Office of the Inspector General for the Centers for Medicare & Medicaid Services found that 10 improperly classified drugs cost the federal program $1.3 billion in four years.

After discovering that Mylan had avoided paying Medicaid tens of millions of dollars in rebates by misclassifying its EpiPen, Congress asked the agency to determine how wide-ranging the problem was. It now has its answer. The number of misclassified drugs is small, but the cost to the cash-strapped Medicaid program is big: hundreds of millions of dollars a year, and most of that comes from just a few drugs.   

While only 3% of the 30,000 drugs reviewed were misclassified, the report found that the cost to Medicaid for the 10 potentially misclassified drugs with the highest total reimbursement, ran to $1.3 billion between 2012 and 2016.

And while the report does not name names of drugs or companies, it found that very few drugmakers are the biggest offenders. Four drugmakers were responsible for more than half of the misclassified drugs, meaning they paid rebates of only about 13%, instead of 23.1%. Only two drugs accounted for 90% of the potentially lost rebates.  

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

RELATED: Sanofi tip ends in $465M settlement between Mylan and DOJ

The investigation by the HHS inspector general was kicked into gear after Mylan, on a tip from competitor Sanofi, was found in 2016 to have been classifying its EpiPen for anaphylactic shock as a generic instead of an innovator drug.

Mylan tried to quickly get beyond the problem by agreeing to a $465 million settlement with the Justice Department. That was far less than estimates from the inspector general, which said the EpiPen Medicaid misclassification cost taxpayers $1.27 billion from 2006 to 2016. Mylan signed a Corporate Integrity Agreement which did not “contain an admission or finding of wrongdoing,” but reclassified its product to pay the higher rebate going forward.

RELATED: Mylan lowballed Medicaid on EpiPen by $1.27B, far more than its DOJ settlement: HHS

While the latest report lays out the extent of the problem, it found that the Centers for Medicare & Medicaid Services does not have the power to fix it short of kicking drugmakers out of Medicaid altogether, a measure it says would create huge problems for patients. When CMS discovers inconsistencies, it asks drugmakers for more information about the classifications but if they refuse to provide it, CMS has no power to compel them. That needs to be changed, the report from the HHS inspector general says.  

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.